Literature DB >> 11309631

Challenges and opportunities for development of an AIDS vaccine.

G J Nabel1.   

Abstract

Among the devastating consequences of AIDS has been its epidemic spread in the developing world. The disease has caused unprecedented suffering, debilitation, loss of life and disruption of family, social and economic stability. Because of the considerable expense and logistical difficulty in providing antiviral drugs to populations infected with the human immunodeficiency virus throughout the world, the biomedical community is looking towards vaccines to help solve this compelling problem.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309631     DOI: 10.1038/35073500

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  52 in total

1.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Protein grafting of an HIV-1-inhibiting epitope.

Authors:  Samuel K Sia; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

3.  Cures for the Third World's problems: the application of genomics to the diseases plaguing the developing world may have huge medical and economic benefits for those countries and might even prevent armed conflict.

Authors:  Samuel Broder; Stephen L Hoffman; Peter J Hotez
Journal:  EMBO Rep       Date:  2002-09       Impact factor: 8.807

Review 4.  Current advances in HIV vaccines.

Authors:  M Patricia D'Souza; Mary Allen; Rebecca Sheets; Margaret I Johnston
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

5.  Augmented designs to assess immune response in vaccine trials.

Authors:  Dean Follmann
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

6.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.

Authors:  Jorge A Tavel; Julie E Martin; Grace G Kelly; Mary E Enama; Jean M Shen; Phillip L Gomez; Charla A Andrews; Richard A Koup; Robert T Bailer; Judy A Stein; Mario Roederer; Gary J Nabel; Barney S Graham
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

8.  Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Authors:  John R Mascola; Anna Sambor; Kristin Beaudry; Sampa Santra; Brent Welcher; Mark K Louder; Thomas C Vancott; Yue Huang; Bimal K Chakrabarti; Wing-Pui Kong; Zhi-Yong Yang; Ling Xu; David C Montefiori; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.